Prioritizing the order of writing guidelines for CPIC genes/drugs is based on the following criteria:
- Is there prescribing actionability?
- What is the severity of the clinical consequences (adverse effects, lack of response) if genetics are not used to inform prescribing?
- Is the gene already subject to other CPIC guidelines?
- Is there an available genetic test for that gene?
- How commonly used are the affected drugs?
- How common are the high-risk genetic variants?
- Is there mention of genetic testing in drug labelling?
- Are there pharmacogenetically-based prescribing recommendations from professional organizations or others?
CPIC guidelines published, in progress, or planned
| Gene – Drug | Current CPIC level* | Status |
| TPMT, NUDT15 – thiopurines | A | Published; update in progress |
| CYP2C19 – clopidogrel | A | Published |
| CYP2C9,VKORC1, CYP4F2 – warfarin | A | Published |
| CYP2D6 – opioids | A | Published |
| HLA-B – abacavir | A | Published |
| SLCO1B1, ABCG2, CYP2C9 – statins | A | Published |
| HLA-B – allopurinol | A | Published |
| CYP2D6, CYP2C19 – TCAs (ABCB1 will be evaluated when updated) | A | Published |
| HLA-B/HLA-A – carbamazepine/oxcarbazepine | A | Published |
| DPYD – 5FU / capecitabine | A | Published; update in progress |
| IFNL3 – pegIntron | A | Published |
| CFTR – Ivacaftor | A | Published |
| G6PD – many drugs | A | Published |
| CYP2C9, HLA-B – phenytoin | A | Published |
| CYP2D6, CYP2C19, CYP2B6 – SSRIs, SNRIs, others | A | Published |
| CYP3A5 – tacrolimus | A | Published; update in progress |
| UGT1A1 – atazanavir | A | Published |
| CYP2C19 – voriconazole | A | Published |
| CYP2D6 – ondansetron/tropisetron | A | Published |
| CYP2D6 – tamoxifen | A | Published |
| RYR1, CACNA1S – inhaled anesthetics | A | Published |
| CYP2B6 – efavirenz | A | Published |
| CYP2D6 – atomoxetine | A | Published |
| CYP2C19 – PPIs (i.e., esomeprazole, omeprazole, etc.) | A | Published |
| CYP2C9 – NSAIDS (celecoxib, flurbiprofen, diclofenac, etc.) | A | Published |
| MTRNR1- aminoglycosides | A | Published |
| CYP2D6 – antipsychotics (aripiprazole, brexpiprazole, pimozide, risperidone, iloperidone, perphenazine, clozapine, haloperidol, olanzapine, thioridazine, zuclopenthixol) | B | In progress |
| UGT1A1/anticancer drugs (irinotecan. nilotinib, belinostat, others) | B | |
| NAT2/hydralazine | A/B | In progress |
| CYP2D6 – B-blockers (carvedilol, metoprolol, propranolol, timolol) | A | Published |
| CYP2B6 – methadone | C | Published |
| CYP2C19 – benzodiazepines (clobazam, diazepam) | B/C | |
| Factor V Leiden – estrogen OC | C | |
| MTHFR – methotrexate/others | C | |
| NAT2 – isoniazid | C | |
| CYP2D6 – pimozide | B | |
| CYP2D6 – antiarrhythmics (quinidine, flecainide, propafenone) | B | |
| CYP2D6 – misc. drugs (eliglustat, dextromethorphan, etc) | B | |
| Genes associated with metabolic disorders (ASL, ASS1, CPS1, NAGS, OTC, GBA, HPRT1, NAGS, POLG, etc) – various drugs (valproic acid, velagluceras alfa, mycophenolic acid, carglumic acid, etc) | B |
*Subject to change. Guidelines authors determine final CPIC level. See here for CPIC level definitions.